Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man - methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials - Scientific guideline

This document is an appendix to the guideline on the evaluation of anticancer medicinal products in man. It provides a guidance on the use of progression-free survival or disease-free survival as endpoint in clinical efficacy trials.

Keywords: Cancer, malignancy, biomarker, targeted drugs, pharmacogenomics

Topics

How useful was this page?

Add your rating